We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
04 April 2018
In its Common Drug Review Update – Issue 133, which was published on February 13 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) announced revisions to its biosimilar and administrative review process.(1) The update:
Other updates include the issuance of new administrative forms, such as:
For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) Further details are available here.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.